Transcode Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Transcode Therapeutics Depreciation & Amortization Growth & History (RNAZ)
Transcode Therapeutics's depreciation and amortization was $76,446 for fiscal 2025.
View full Transcode Therapeutics company overviewTranscode Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $76,446 | −$14,448 | −15.90% |
| 2024 | 2024-12-31 | $90,894 | −$32,589 | −26.39% |
| 2023 | 2023-12-31 | $123,483 | $24,877 | +25.23% |
| 2022 | 2022-12-31 | $98,606 | $56,136 | +132.18% |
| 2021 | 2021-12-31 | $42,470 | $42,470 | — |
| 2020 | 2020-12-31 | $0 | — | — |
Transcode Therapeutics quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $23,937 | $10,494 | +78.06% |
| Q1 2026 | 2026-03-31 | $23,936 | $10,493 | +78.06% |
| Q4 2025 | 2025-12-31 | $44,780 | — | — |
| Q3 2025 | 2025-09-30 | $4,781 | −$11,250 | −70.18% |
| Q2 2025 | 2025-06-30 | $13,443 | −$18,911 | −58.45% |
| Q1 2025 | 2025-03-31 | $13,443 | −$18,721 | −58.20% |
| Q3 2024 | 2024-09-30 | $16,031 | −$15,187 | −48.65% |
| Q2 2024 | 2024-06-30 | $32,354 | $1,384 | +4.47% |
| Q1 2024 | 2024-03-31 | $32,164 | $2,524 | +8.52% |
| Q3 2023 | 2023-09-30 | $31,218 | $6,416 | +25.87% |
| Q2 2023 | 2023-06-30 | $30,970 | $8,272 | +36.44% |
| Q1 2023 | 2023-03-31 | $29,640 | $8,039 | +37.22% |
| Q3 2022 | 2022-09-30 | $24,802 | $12,574 | +102.83% |
| Q2 2022 | 2022-06-30 | $22,698 | $18,005 | +383.66% |
| Q1 2022 | 2022-03-31 | $21,601 | $20,347 | +1622.57% |
| Q3 2021 | 2021-09-30 | $12,228 | — | — |
| Q2 2021 | 2021-06-30 | $4,693 | — | — |
| Q1 2021 | 2021-03-31 | $1,254 | — | — |
Transcode Therapeutics depreciation and amortization trends
Over the last five fiscal years, Transcode Therapeutics's depreciation and amortization increased from $0 to $76,446, a change of $76,446. The latest reported quarter, Q2 2026, shows $23,937.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transcode Therapeutics source filings ↗